The S-1 clone of dengue type 2 virus was used for the preparation of a liveattenuated vaccine after passage in DBS-FRhL-2 cell culture. The vaccine virus had a relatively higher replicative capacity at superoptimal temperatures than its precursor virus, S-1, passaged in primary green monkey kidney cells (S-i PGMK).
There was also a tendency for the S-1 vaccine virus to exhibit leakiness at increased temperatures. Another in vitro marker, replication in monkey peripheral blood leukocytes, indicated less host restriction for the S-1 vaccine in comparative assays with S-1 PGMK virus. Mouse virulence appeared to remain stable on passage in DBS-FRhL-2 cells, whereas monkey immunogenicity decreased. Cautious trials of the dengue type 2 S-1 vaccine in humans are indicated.
Dengue and dengue hemorrhagic fever occur in endemic or epidemic form throughout tropical areas of the world. In the Americas, dengue types 2 and 3 (DEN-2 and DEN-3) and, most recently, DEN-1, have been associated with widespread epidemics of dengue fever (2, 10, 18) . In Southeast Asia, dengue hemorrhagic fever is a major public health problem. Widespread epidemics causing significant mortality in the pediatric age group have increased markedly in the last decade. Vector control is the only preventive measure available, but to date this has been ineffective in many areas.
The feasibility of producing live-attenuated vaccines for DEN-1 (7, 12) and DEN-2 (13) viruses has been investigated. These early vaccines used virus modified by passage in mouse brain. Modification was judged by the reduction in the severity or the complete loss of clinical signs of disease in humans. These vaccines, along with another mouse brain vaccine prepared by Wisseman et al. (19) , were shown to be effective and to have low reactogenicity.
Present-day methodology has made it possible to select temperature-sensitive and host-restricted, conditional lethal mutants of many viruses. Several flavivirus mutants with reduced animal virulence have been studied on a limited scale. These include Japanese encephalitis (3, 5) , tick-borne encephalitis (8) , Langat (9), Kyasanur Forest (11), and DEN-2 (la, 15, 16) [6] as S-1 p-19a) was used to inoculate DBS-FRhL-2 monolayers. After two passages in 25-cm2 flasks, the S-1 virus was inoculated into 700-cm2 roller flasks. Viral inocula were diluted so that a low multiplicity of infection (MOI) was used to prevent reversion to large-plaque, temperature-resistant virus (la) . Supernatant fluids were harvested between days 7 and 10 and were assayed for infectious virus by plaquing at 35 and 39.30C.
Tests for adventitious microbial agents in the production seed virus pool were performed as described (la) albumin, 0.22% NaHCO3, streptomycin (50.ug/ml), and neomycin (100 ,ug/ml). Medium on all flasks was changed on day 4, and supernatant fluids were harvested on day 6 . Before centrifugation at 1,050 x g for 20 min, human serum albumin was added to supernatant fluids, resulting in a final concentration of 2.75%. The pH of the albumin was adjusted to 7.6 before addition to the virus fluids. As a final step in clarification, fluids were filtered through a 0.45-,um membrane filter (Nalge, Rochester, N.Y.). After removal of samples for safety testing and plaque assay, the remaining volume was held in ice baths in a 40C refrigerator for 7 days pending results of sterility and plaque assays. A final pool of vaccine was made by using virus fluids from flasks containing <5 plaque-forming units (PFU)/ml at 39.30C and with no detectable largeplaque virus at 350C. The titer of the vaccine pool was 5.5 x 104 PFU/ml. After freeze-drying in 3-ml amounts, the average titer for 10 vials was 8.5 x 104 PFU/ml, with no detectable large-plaque virus present. The infectivity of freeze-dried vaccine held at -20°C has remained stable for a period of approximately 2.5 years.
Safety tests on supernatant fluids before centrifugation were identical to those performed on the vaccine seed preparation. Final container tests for 25 vials of vaccine included bacterial sterility and the inoculation of two young adult mice and two guinea pigs. All tests were negative, indicating the absence of any adventitious agents in the DEN-2 vaccine, lot no. 1. Neurovirulence testing of vaccine has been described in detail elsewhere (6) . Eleven male rhesus monkeys were inoculated intracerebrally into each hemisphere and intraspinally, using 0. 9 months previously with DEN-3 virus, was mixed with an equal volume of Ca-and Mg-free HBSS. Fifteen milliliters of Ficoll-Hypaque was layered under 35 ml of the diluted, heparinized blood and centrifuged at 350 x g for 40 min. The leukocyte band was removed and washed once in HBSS and once in RPMI 1640 medium containing 10% FBS, 2 mM glutamine, 0.01 M HEPES buffer (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), and antibiotics. Cells were resuspended in RPMI 1640 medium and adjusted to a concentration of 6.8 x 10' cells/ml before inoculation of the suspension with virus. Growth curves were performed at 350C.
Monkey immunogenicity studies. Details of monkey inoculation experiments and procedures for testing complement-fixing, hemagglutination inhibition, and neutralizing antibodies have been described elsewhere (6, 14 310C. The effect of temperature on the emergence oftemperature-resistant virus was assayed for both the S-1 vaccine and S-1 PGMK viruses by growth at 310C, 350C, and 370C. Table 2 lists the 7-day harvest titers of these viruses plaqued at 350C as well as the number of cell culture flasks containing virus which plaqued at 39.30C. The S-1 vaccine-inoculated flasks showed an increase in the percentage of flasks with temperature-resistant virus as a function of increased temperature. At 370C, 65% of these flasks contained virus in supernatant culture fluids that formed plaques at 39.30C, whereas no temperature-resistant virus was found in any of the infected flasks at 310C. None of the S-1 PGMK virus-inoculated cell culture flasks at 31, 35, or 370C was found to contain temperature-resistant virus; however, virus titers were appreciably lower at all temperatures than virus from flasks inoculated with S-1 vaccine virus. Lower virus titers may account for the inability to demonstrate this phenomenon with the S-1 PGMK virus.
Individual plaque isolates were made from plaques formed at 39.30C in four S-1 vaccineinoculated flasks incubated originally at 370C. The plaque picks were inoculated into LLC-MK2 flasks incubated at 350C, and the supernatant fluids were harvested after 14 days. Assays of the clone harvests from seven plaque picks listed in Table 3 Plaques selected for cloning were from a 39.30C assay of S-1 vaccine virus grown at 370C.
Replication in monkey PBL cultures. Halstead and O'Rourke (4) demonstrated that replication of dengue virus occurred in monkey PBL cultures when the PBL were from a dengueimmune monkey or when a nonimmune cell donor was used and diluted dengue antibody was added to the culture system. Cells from a cynomolgus monkey, previously immunized with DEN-3, were inoculated with S-1 vaccine and S-1 PGMK viruses at an MOI of approximately 0.015. Human antiserum with a DEN-2 neutralization titer of 1:80, previously shown to enhance dengue virus replication in human monocytes (1), was added to cell culture medium at a final dilution of 1:500. Both dengue-immune monkey PBL and addition of diluted homologous antibody were used for maximal enhancement of growth of the S-1 viruses. On days 2, 3, and 4 postinfection, triplicate vials were frozen at -70'C and later assayed in LLC-MK2 cells. Growth curves plotted in Fig. 2 indicate that the S-1 vaccine virus grew to higher titer than the S-1 PGMK virus in monkey PBL cultures. In addition to temperature restriction, which was previously seen for S-1 PGMK virus, host restriction of this virus was demonstrated in the PBL growth curves.
Mouse neurovirulence. Suckling mouse neurovirulence for the S-1 clone is less than that of the parent virus (la) . Death of mice after intracerebral inoculation of S-1 virus is used as a measure of virulence and compared with the plaque titer of the S-1 virus assayed in LLC-MK2 cells. The virulence ratios for S-1 PGMK and S-1 vaccine viruses are listed in Table 4 . (14) . DISCUSSION In vitro markers including replication and plaque formation at superoptimal temperatures in LLC-MK2 monolayers, as well as replication in monkey PBL cell suspensions, indicate a greater capacity for the S-1 vaccine virus to overcome temperature or host restriction than the S-1 PGMK virus. Similarly, superior replication of the S-1 vaccine virus in comparative growth curves with S-1 PGMK virus using human monocytes has recently been demonstrated (1) . In addition, it appears that the S-1 vaccine can generate leaky virus at 370C, whereas this temperature-dependent phenomenon was not seen for S-1 PGMK virus. The only marker examined where no difference could be detected between the two viruses was mouse neurovirulence.
Previously, loss of attenuation for the S-1 clone was correlated with the emergence of a large-plaque, temperature-resistant population of virus which appeared to be revertant (la) . The concomitant increase in mouse and monkey virulence made it appear that these properties of the S-1 clone were covariant. In the present study, the S-1 clone passaged in DBS-FRhL-2 cells appeared to gain some degree of temperature resistance without emergence of largeplaque, revertant virus or an increase in animal virulence.
Another change in the virus that could be measured was a significant decrease in immunogenicity of the virus for monkeys. Reduced immunogenicity for monkeys may be associated with a lower capacity for the S-1 vaccine to replicate in the host animal. It is not possible to demonstrate this directly at the present time, and in vitro markers indicate no decreased replicative capacity for the S-1 vaccine.
Selection for a variant of the S-1 clone may have occurred during passage in DBS-FRhL-2 cells. However, there appears to be no detectable virus population with an altered temperaturesensitive phenotype or increased plaque size. Host modification of viral infectivity and possibly also immunogenicity may have played some part in the observed changes in the clone upon passage.
Although the S-1 vaccine virus demonstrates DENGUE-2 VACCINE PREPARATION 179 leakiness when it is grown at 370C, there is no evidence of reversion. There is also no indication that the S-1 clone reverts in rhesus monkeys or chimps (6) . In addition to the relative stability of the clone, there were minimal changes in the temperature-sensitive phenotype and lack ofany measurable neurovirulence in monkeys. Examination of these and other characteristics of the S-1 vaccine prepared in DBS-FRhL-2 cells indicates that this vaccine is a reasonably safe and potentially useful immunogen for humans.
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